Moderna fully enrolls phase 3 trial for COVID-19 vaccine candidate, with heavy emphasis on traditionally under-represented communities

Oct 22, 2020 - 02:45 PM
COVID19 Web Sized

Moderna Inc., today announced the completion of enrollment for its COVID-19 vaccine phase 3 trial.

The drug maker said that it has confirmed 30,000 participants for an efficacy study of mRNA-1273. Moderna and the National Institute of Allergy and Infectious Diseases developed the candidate, which generated a strong immune response in older adults during its phase 1 clinical trial.

Communities that have historically been under-represented in clinical research and are disproportionately impacted by COVID-19 have significant representation among the trial enrollees. Moderna said the study includes more than 11,000 participants from communities of color, representing 37% of the study population and similar to the diversity of the U.S. at large. This includes more than 6,000 participants who identify as Hispanic or Latinx, and more than 3,000 participants who identify as Black or African American.

Related News Articles

Headline
FDA seeks feedback on measuring AI-enabled medical device performance
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
Olympus recalls endoscope needles
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
HHS announces efforts to improve long COVID care 
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
CDC releases 2025-26 respiratory disease season outlook
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…